Global and United States Waldenstrom Macroglobulinemia Therapeutics Market Report & Forecast 2024-2031

Report ID: 1838698 | Published Date: Sep 2024 | No. of Page: 104 | Base Year: 2023 | Rating: 3.7 | Webstory: Check our Web story
1 Study Coverage
    1.1 Waldenstrom Macroglobulinemia Therapeutics Product Introduction
    1.2 Global Waldenstrom Macroglobulinemia Therapeutics Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales in US$ Million for the Year 2017-2028
        1.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Volume for the Year 2017-2028
    1.3 United States Waldenstrom Macroglobulinemia Therapeutics Outlook 2017 VS 2022 VS 2028
        1.3.1 United States Waldenstrom Macroglobulinemia Therapeutics Sales in US$ Million for the Year 2017-2028
        1.3.2 United States Waldenstrom Macroglobulinemia Therapeutics Sales in Volume for the Year 2017-2028
    1.4 Waldenstrom Macroglobulinemia Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.4.1 The Market Share of United States Waldenstrom Macroglobulinemia Therapeutics in Global, 2017 VS 2022 VS 2028
        1.4.2 The Growth Rate of Waldenstrom Macroglobulinemia Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.5 Waldenstrom Macroglobulinemia Therapeutics Market Dynamics
        1.5.1 Waldenstrom Macroglobulinemia Therapeutics Industry Trends
        1.5.2 Waldenstrom Macroglobulinemia Therapeutics Market Drivers
        1.5.3 Waldenstrom Macroglobulinemia Therapeutics Market Challenges
        1.5.4 Waldenstrom Macroglobulinemia Therapeutics Market Restraints
    1.6 Study Objectives
    1.7 Years Considered
2 Market by Type
    2.1 Waldenstrom Macroglobulinemia Therapeutics Market Segment by Type
        2.1.1 CB-839
        2.1.2 Copanlisib Hydrochloride
        2.1.3 DI-B4
        2.1.4 Entospletinib
        2.1.5 Everolimus
        2.1.6 FV-162
        2.1.7 Others
    2.2 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
        2.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Value, by Type (2017, 2022 & 2028)
        2.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Volume, by Type (2017, 2022 & 2028)
        2.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Average Selling Price (ASP) by Type (2017, 2022 & 2028)
    2.3 United States Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
        2.3.1 United States Waldenstrom Macroglobulinemia Therapeutics Sales in Value, by Type (2017, 2022 & 2028)
        2.3.2 United States Waldenstrom Macroglobulinemia Therapeutics Sales in Volume, by Type (2017, 2022 & 2028)
        2.3.3 United States Waldenstrom Macroglobulinemia Therapeutics Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
    3.1 Waldenstrom Macroglobulinemia Therapeutics Market Segment by Application
        3.1.1 Clinic
        3.1.2 Hospital
        3.1.3 Others
    3.2 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
        3.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Value, by Application (2017, 2022 & 2028)
        3.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 Global Waldenstrom Macroglobulinemia Therapeutics Average Selling Price (ASP) by Application (2017, 2022 & 2028)
    3.3 United States Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
        3.3.1 United States Waldenstrom Macroglobulinemia Therapeutics Sales in Value, by Application (2017, 2022 & 2028)
        3.3.2 United States Waldenstrom Macroglobulinemia Therapeutics Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 United States Waldenstrom Macroglobulinemia Therapeutics Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Waldenstrom Macroglobulinemia Therapeutics Competitor Landscape by Company
    4.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Company
        4.1.1 Top Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers Ranked by Revenue (2021)
        4.1.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Manufacturer (2017-2022)
        4.1.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Manufacturer (2017-2022)
        4.1.4 Global Waldenstrom Macroglobulinemia Therapeutics Price by Manufacturer (2017-2022)
    4.2 Global Waldenstrom Macroglobulinemia Therapeutics Concentration Ratio (CR)
        4.2.1 Waldenstrom Macroglobulinemia Therapeutics Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Waldenstrom Macroglobulinemia Therapeutics in 2021
        4.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Waldenstrom Macroglobulinemia Therapeutics Manufacturing Base Distribution, Product Type
        4.3.1 Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers, Headquarters and Distribution of Producing Region
        4.3.2 Manufacturers Waldenstrom Macroglobulinemia Therapeutics Product Type
        4.3.3 Date of International Manufacturers Enter into Waldenstrom Macroglobulinemia Therapeutics Market
    4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
    4.5 United States Waldenstrom Macroglobulinemia Therapeutics Market Size by Company
        4.5.1 Top Waldenstrom Macroglobulinemia Therapeutics Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Waldenstrom Macroglobulinemia Therapeutics Revenue by Players (2020, 2021 & 2022)
        4.5.3 United States Waldenstrom Macroglobulinemia Therapeutics Sales by Players (2020, 2021 & 2022)
5 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Region
    5.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Waldenstrom Macroglobulinemia Therapeutics Market Size in Volume by Region (2017-2028)
        5.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Volume by Region: 2017-2022
        5.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Volume Forecast by Region (2023-2028)
    5.3 Global Waldenstrom Macroglobulinemia Therapeutics Market Size in Value by Region (2017-2028)
        5.3.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Region: 2017-2022
        5.3.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth 2017-2028
        6.1.2 North America Waldenstrom Macroglobulinemia Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth 2017-2028
        6.3.2 Europe Waldenstrom Macroglobulinemia Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth 2017-2028
        6.4.2 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 U.A.E
7 Company Profiles
    7.1 BeiGene (Beijing) Co.,Ltd
        7.1.1 BeiGene (Beijing) Co.,Ltd Corporation Information
        7.1.2 BeiGene (Beijing) Co.,Ltd Description and Business Overview
        7.1.3 BeiGene (Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.1.4 BeiGene (Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Products Offered
        7.1.5 BeiGene (Beijing) Co.,Ltd Recent Development
    7.2 Calithera Biosciences, Inc.
        7.2.1 Calithera Biosciences, Inc. Corporation Information
        7.2.2 Calithera Biosciences, Inc. Description and Business Overview
        7.2.3 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.2.4 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Products Offered
        7.2.5 Calithera Biosciences, Inc. Recent Development
    7.3 Celgene Corporation
        7.3.1 Celgene Corporation Corporation Information
        7.3.2 Celgene Corporation Description and Business Overview
        7.3.3 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.3.4 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Products Offered
        7.3.5 Celgene Corporation Recent Development
    7.4 Genentech, Inc.
        7.4.1 Genentech, Inc. Corporation Information
        7.4.2 Genentech, Inc. Description and Business Overview
        7.4.3 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.4.4 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Products Offered
        7.4.5 Genentech, Inc. Recent Development
    7.5 Genmab A/S
        7.5.1 Genmab A/S Corporation Information
        7.5.2 Genmab A/S Description and Business Overview
        7.5.3 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.5.4 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Products Offered
        7.5.5 Genmab A/S Recent Development
    7.6 Gilead Sciences, Inc.
        7.6.1 Gilead Sciences, Inc. Corporation Information
        7.6.2 Gilead Sciences, Inc. Description and Business Overview
        7.6.3 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.6.4 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Products Offered
        7.6.5 Gilead Sciences, Inc. Recent Development
    7.7 Hutchison MediPharma Limited
        7.7.1 Hutchison MediPharma Limited Corporation Information
        7.7.2 Hutchison MediPharma Limited Description and Business Overview
        7.7.3 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.7.4 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Products Offered
        7.7.5 Hutchison MediPharma Limited Recent Development
    7.8 Idera Pharmaceuticals, Inc.
        7.8.1 Idera Pharmaceuticals, Inc. Corporation Information
        7.8.2 Idera Pharmaceuticals, Inc. Description and Business Overview
        7.8.3 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.8.4 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Products Offered
        7.8.5 Idera Pharmaceuticals, Inc. Recent Development
    7.9 IGF Oncology, LLC.
        7.9.1 IGF Oncology, LLC. Corporation Information
        7.9.2 IGF Oncology, LLC. Description and Business Overview
        7.9.3 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.9.4 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Products Offered
        7.9.5 IGF Oncology, LLC. Recent Development
    7.10 Incyte Corporation
        7.10.1 Incyte Corporation Corporation Information
        7.10.2 Incyte Corporation Description and Business Overview
        7.10.3 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.10.4 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Products Offered
        7.10.5 Incyte Corporation Recent Development
    7.11 Karyopharm Therapeutics, Inc.
        7.11.1 Karyopharm Therapeutics, Inc. Corporation Information
        7.11.2 Karyopharm Therapeutics, Inc. Description and Business Overview
        7.11.3 Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.11.4 Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Products Offered
        7.11.5 Karyopharm Therapeutics, Inc. Recent Development
    7.12 Merck KGaA
        7.12.1 Merck KGaA Corporation Information
        7.12.2 Merck KGaA Description and Business Overview
        7.12.3 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.12.4 Merck KGaA Products Offered
        7.12.5 Merck KGaA Recent Development
    7.13 Millennium Pharmaceuticals, Inc.
        7.13.1 Millennium Pharmaceuticals, Inc. Corporation Information
        7.13.2 Millennium Pharmaceuticals, Inc. Description and Business Overview
        7.13.3 Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        7.13.4 Millennium Pharmaceuticals, Inc. Products Offered
        7.13.5 Millennium Pharmaceuticals, Inc. Recent Development
8 Industry Chain and Sales Channels Analysis
    8.1 Waldenstrom Macroglobulinemia Therapeutics Industry Chain Analysis
    8.2 Waldenstrom Macroglobulinemia Therapeutics Key Raw Materials
        8.2.1 Key Raw Materials
        8.2.2 Waldenstrom Macroglobulinemia Therapeutics Distributors
    8.3 Waldenstrom Macroglobulinemia Therapeutics Production Mode & Process
    8.4 Waldenstrom Macroglobulinemia Therapeutics Sales and Marketing
        8.4.1 Waldenstrom Macroglobulinemia Therapeutics Sales Channels
        8.4.2 Waldenstrom Macroglobulinemia Therapeutics Distributors
    8.5 Waldenstrom Macroglobulinemia Therapeutics Customers
9 Research Findings and Conclusion
10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer
List of Tables
    Table 1. Waldenstrom Macroglobulinemia Therapeutics CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Waldenstrom Macroglobulinemia Therapeutics Market Trends
    Table 3. Waldenstrom Macroglobulinemia Therapeutics Market Drivers
    Table 4. Waldenstrom Macroglobulinemia Therapeutics Market Challenges
    Table 5. Waldenstrom Macroglobulinemia Therapeutics Market Restraints
    Table 6. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Waldenstrom Macroglobulinemia Therapeutics Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Waldenstrom Macroglobulinemia Therapeutics Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Waldenstrom Macroglobulinemia Therapeutics Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Manufacturer, (K Pcs), 2017-2022
    Table 14. Global Waldenstrom Macroglobulinemia Therapeutics Sales Share by Manufacturer, 2017-2022
    Table 15. Global Waldenstrom Macroglobulinemia Therapeutics Price by Manufacturer (2017-2022) & (USD/Pcs)
    Table 16. Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Waldenstrom Macroglobulinemia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Waldenstrom Macroglobulinemia Therapeutics as of 2021)
    Table 18. Top Players of Waldenstrom Macroglobulinemia Therapeutics in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Waldenstrom Macroglobulinemia Therapeutics Product Type
    Table 20. Date of International Manufacturers Enter into Waldenstrom Macroglobulinemia Therapeutics Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Waldenstrom Macroglobulinemia Therapeutics Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Waldenstrom Macroglobulinemia Therapeutics Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Waldenstrom Macroglobulinemia Therapeutics Sales by Players, (K Pcs), 2020, 2021 & 2022
    Table 26. United States Waldenstrom Macroglobulinemia Therapeutics Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Waldenstrom Macroglobulinemia Therapeutics Sales in Volume by Region (2017-2022) & (K Pcs)
    Table 29. Global Waldenstrom Macroglobulinemia Therapeutics Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
    Table 30. Global Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Waldenstrom Macroglobulinemia Therapeutics Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Waldenstrom Macroglobulinemia Therapeutics Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 33. North America Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Sales in Volume by Region (2017-2028) & (K Pcs)
    Table 35. Asia Pacific Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Waldenstrom Macroglobulinemia Therapeutics Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 37. Europe Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 39. Latin Americaa Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 41. Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. BeiGene (Beijing) Co.,Ltd Corporation Information
    Table 43. BeiGene (Beijing) Co.,Ltd Description and Business Overview
    Table 44. BeiGene (Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 45. BeiGene (Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Product
    Table 46. BeiGene (Beijing) Co.,Ltd Recent Development
    Table 47. Calithera Biosciences, Inc. Corporation Information
    Table 48. Calithera Biosciences, Inc. Description and Business Overview
    Table 49. Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 50. Calithera Biosciences, Inc. Product
    Table 51. Calithera Biosciences, Inc. Recent Development
    Table 52. Celgene Corporation Corporation Information
    Table 53. Celgene Corporation Description and Business Overview
    Table 54. Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 55. Celgene Corporation Product
    Table 56. Celgene Corporation Recent Development
    Table 57. Genentech, Inc. Corporation Information
    Table 58. Genentech, Inc. Description and Business Overview
    Table 59. Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 60. Genentech, Inc. Product
    Table 61. Genentech, Inc. Recent Development
    Table 62. Genmab A/S Corporation Information
    Table 63. Genmab A/S Description and Business Overview
    Table 64. Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 65. Genmab A/S Product
    Table 66. Genmab A/S Recent Development
    Table 67. Gilead Sciences, Inc. Corporation Information
    Table 68. Gilead Sciences, Inc. Description and Business Overview
    Table 69. Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 70. Gilead Sciences, Inc. Product
    Table 71. Gilead Sciences, Inc. Recent Development
    Table 72. Hutchison MediPharma Limited Corporation Information
    Table 73. Hutchison MediPharma Limited Description and Business Overview
    Table 74. Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 75. Hutchison MediPharma Limited Product
    Table 76. Hutchison MediPharma Limited Recent Development
    Table 77. Idera Pharmaceuticals, Inc. Corporation Information
    Table 78. Idera Pharmaceuticals, Inc. Description and Business Overview
    Table 79. Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 80. Idera Pharmaceuticals, Inc. Product
    Table 81. Idera Pharmaceuticals, Inc. Recent Development
    Table 82. IGF Oncology, LLC. Corporation Information
    Table 83. IGF Oncology, LLC. Description and Business Overview
    Table 84. IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 85. IGF Oncology, LLC. Product
    Table 86. IGF Oncology, LLC. Recent Development
    Table 87. Incyte Corporation Corporation Information
    Table 88. Incyte Corporation Description and Business Overview
    Table 89. Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 90. Incyte Corporation Product
    Table 91. Incyte Corporation Recent Development
    Table 92. Karyopharm Therapeutics, Inc. Corporation Information
    Table 93. Karyopharm Therapeutics, Inc. Description and Business Overview
    Table 94. Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 95. Karyopharm Therapeutics, Inc. Product
    Table 96. Karyopharm Therapeutics, Inc. Recent Development
    Table 97. Merck KGaA Corporation Information
    Table 98. Merck KGaA Description and Business Overview
    Table 99. Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 100. Merck KGaA Product
    Table 101. Merck KGaA Recent Development
    Table 102. Millennium Pharmaceuticals, Inc. Corporation Information
    Table 103. Millennium Pharmaceuticals, Inc. Description and Business Overview
    Table 104. Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 105. Millennium Pharmaceuticals, Inc. Product
    Table 106. Millennium Pharmaceuticals, Inc. Recent Development
    Table 107. Key Raw Materials Lists
    Table 108. Raw Materials Key Suppliers Lists
    Table 109. Waldenstrom Macroglobulinemia Therapeutics Customers List
    Table 110. Waldenstrom Macroglobulinemia Therapeutics Distributors List
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Waldenstrom Macroglobulinemia Therapeutics Product Picture
    Figure 2. Global Waldenstrom Macroglobulinemia Therapeutics Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Waldenstrom Macroglobulinemia Therapeutics Market Size 2017-2028 (US$ Million)
    Figure 4. Global Waldenstrom Macroglobulinemia Therapeutics Sales 2017-2028 (K Pcs)
    Figure 5. United States Waldenstrom Macroglobulinemia Therapeutics Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Waldenstrom Macroglobulinemia Therapeutics Market Size 2017-2028 (US$ Million)
    Figure 7. United States Waldenstrom Macroglobulinemia Therapeutics Sales 2017-2028 (K Pcs)
    Figure 8. United States Waldenstrom Macroglobulinemia Therapeutics Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Waldenstrom Macroglobulinemia Therapeutics Market Share in Global, in Volume (K Pcs) 2017-2028
    Figure 10. Waldenstrom Macroglobulinemia Therapeutics Report Years Considered
    Figure 11. Product Picture of CB-839
    Figure 12. Product Picture of Copanlisib Hydrochloride
    Figure 13. Product Picture of DI-B4
    Figure 14. Product Picture of Entospletinib
    Figure 15. Product Picture of Everolimus
    Figure 16. Product Picture of FV-162
    Figure 17. Product Picture of Others
    Figure 18. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Type in 2022 & 2028
    Figure 19. Global Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 20. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Type (2017-2028)
    Figure 21. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2017-2028) & (K Pcs)
    Figure 22. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Type (2017-2028)
    Figure 23. Global Waldenstrom Macroglobulinemia Therapeutics Price by Type (2017-2028) & (USD/Pcs)
    Figure 24. United States Waldenstrom Macroglobulinemia Therapeutics Market Share by Type in 2022 & 2028
    Figure 25. United States Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 26. United States Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Type (2017-2028)
    Figure 27. United States Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2017-2028) & (K Pcs)
    Figure 28. United States Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Type (2017-2028)
    Figure 29. United States Waldenstrom Macroglobulinemia Therapeutics Price by Type (2017-2028) & (USD/Pcs)
    Figure 30. Product Picture of Clinic
    Figure 31. Product Picture of Hospital
    Figure 32. Product Picture of Others
    Figure 33. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Application in 2022 & 2028
    Figure 34. Global Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 35. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Application (2017-2028)
    Figure 36. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2017-2028) & (K Pcs)
    Figure 37. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Application (2017-2028)
    Figure 38. Global Waldenstrom Macroglobulinemia Therapeutics Price by Application (2017-2028) & (USD/Pcs)
    Figure 39. United States Waldenstrom Macroglobulinemia Therapeutics Market Share by Application in 2022 & 2028
    Figure 40. United States Waldenstrom Macroglobulinemia Therapeutics Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 41. United States Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Value by Application (2017-2028)
    Figure 42. United States Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2017-2028) & (K Pcs)
    Figure 43. United States Waldenstrom Macroglobulinemia Therapeutics Sales Market Share in Volume by Application (2017-2028)
    Figure 44. United States Waldenstrom Macroglobulinemia Therapeutics Price by Application (2017-2028) & (USD/Pcs)
    Figure 45. North America Waldenstrom Macroglobulinemia Therapeutics Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 46. North America Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 47. U.S. Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Canada Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Europe Waldenstrom Macroglobulinemia Therapeutics Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 50. Europe Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 51. Germany Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. France Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. U.K. Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Italy Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Russia Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 57. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 58. China Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Japan Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. South Korea Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. India Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Australia Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Taiwan Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Indonesia Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Thailand Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Malaysia Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Philippines Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 69. Latin America Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 70. Mexico Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Brazil Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Argentina Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 74. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 75. Turkey Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 76. Saudi Arabia Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 77. U.A.E Waldenstrom Macroglobulinemia Therapeutics Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 78. Waldenstrom Macroglobulinemia Therapeutics Value Chain
    Figure 79. Waldenstrom Macroglobulinemia Therapeutics Production Process
    Figure 80. Channels of Distribution
    Figure 81. Distributors Profiles
    Figure 82. Bottom-up and Top-down Approaches for This Report
    Figure 83. Data Triangulation
    Figure 84. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
BeiGene (Beijing) Co.,Ltd
Calithera Biosciences, Inc.
Celgene Corporation
Genentech, Inc.
Genmab A/S
Gilead Sciences, Inc.
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
IGF Oncology, LLC.
Incyte Corporation
Karyopharm Therapeutics, Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Frequently Asked Questions
Waldenstrom Macroglobulinemia Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Waldenstrom Macroglobulinemia Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Waldenstrom Macroglobulinemia Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Emphysema Drug

Emphysema Drug market is segmented by region (country), players, by Type and by Application. Play ... Read More

Interleukin 17A

Interleukin 17A market is segmented by region (country), players, by Type and by Application. Pla ... Read More